Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02489305|
Recruitment Status : Recruiting
First Posted : July 3, 2015
Last Update Posted : January 12, 2018
|Condition or disease|
|Depressive Disorder, Major|
|Study Type :||Observational|
|Estimated Enrollment :||330 participants|
|Official Title:||A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects With Major Depressive Disorder Who Have Responded to Antidepressant Treatment|
|Actual Study Start Date :||December 15, 2014|
|Estimated Primary Completion Date :||April 30, 2018|
|Estimated Study Completion Date :||May 1, 2018|
Participants With Major Depressive Disorder
Participants with major depressive disorder who have responded to oral antidepressant treatment will be observed over time.
- Number of Participants With Near Term Relapse [ Time Frame: Baseline up to end of study (8 Weeks) ]Relapse will be defined as any of the following: a) MADRS total score greater than or equal to 22 on at least two consecutive visits, with an interval of 1-2 weeks; b) Hospitalization for worsening of depression; c) Suicidal ideation with intent, or suicidal behavior and d) Other (investigator will be asked to describe). MADRS total score ranges from 0 to 60, Higher scores represents a more severe condition.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02489305
|Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:||JNJ.CT@sylogent.com|
Show 28 Study Locations
|Study Director:||Janssen Research & Development, LLC Clinical Trials||Janssen Research & Development, LLC|